On October 13, 2025, IceCure Medical Ltd. announced its participation at Aptitude Health's TME Take the Lead in Breast Cancer Care Fall Summit 2025, which took place on September 26–27, 2025, in New Orleans, Louisiana. The high-level roundtable convened over 40 Key Opinion Leaders (KOLs) from across the U.S., including leading breast surgeons, medical oncologists, and interventional radiologists, to advance multidisciplinary care for breast cancer patients.
Cryoablation was prominently featured during a multidisciplinary de-escalation session, illustrating its growing relevance in breast oncology treatment planning. ProSense® and IceCure received significant interest during a cryoablation faculty led by Dr. Richard Fine, a leading investigator of IceCure's ICE3 trial. The company delivered a product showcase presentation focusing on ProSense®'s capabilities and its potential as an unprecedented option for women with low-risk breast cancer.
IceCure's CEO, Eyal Shamir, noted that the inclusion of cryoablation in the de-escalation dialogue underscores the momentum building around less-invasive breast cancer strategies. The high level of interest from top clinicians is expected to translate into clinical adoption, especially following the FDA's marketing authorization for ProSense® in low-risk breast cancer on October 3, 2025, which occurred in the days immediately following the TME Summit.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.